%0 Journal Article
%A Muñoz-Gómez, Ana
%A Fernández-Cruz, Ana
%A Lavilla-Olleros, Cristina
%A Giner-Galvañ, Vicente
%A Ausín-García, Cristina
%A Wikman, Philip
%A Bendala-Estrada, Alejandro D.
%A Vargas, Juan A.
%A Rubio-Rivas, Manuel
%A Laureiro, Jaime
%A Fernández-Bermúdez, Daniel
%A Buonaiuto, Verónica A.
%A Arenas de Larriva, Antonio P.
%A Pascual-Pérez, María de Los Reyes
%A Alcalá-Pedrajas, José N.
%A Labirua-Iturburu Ruiz, Ane
%A Hernández-Milián, Almudena
%A Gómez Del Mazo, Marta
%A Antequera, Beatriz
%A Mella-Pérez, Carmen
%A Navas-Alcántara, María de la Sierra
%A Soto-Delgado, Juan F.
%A Gámez-Mancera, Rosa M.
%A Sardiña-González, Cristina
%A Meijide-Míguez, Héctor
%A Ramos-Rincón, José M.
%A Gómez-Huelgas, Ricardo
%A On Behalf Of The Semi-Covid-Network
%T Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study
%D 2021
%U http://hdl.handle.net/10668/4031
%X We aimed to determine the impact of steroid use in COVID-19 in-hospital mortality, in a retrospective cohort study of the SEMICOVID19 database of admitted patients with SARS-CoV-2 laboratory-confirmed pneumonia from 131 Spanish hospitals. Patients treated with corticosteroids were compared to patients not treated with corticosteroids; and adjusted using a propensity-score for steroid treatment. From March-July 2020, 5.262 (35.26%) were treated with corticosteroids and 9.659 (64.73%) were not. In-hospital mortality overall was 20.50%; it was higher in patients treated with corticosteroids than in controls (28.5% versus 16.2%, OR 2.068 [95% confidence interval; 1.908 to 2.242]; p = 0.0001); however, when adjusting by occurrence of ARDS, mortality was significantly lower in the steroid group (43.4% versus 57.6%; OR 0.564 [95% confidence interval; 0.503 to 0.633]; p = 0.0001). Moreover, the greater the respiratory failure, the greater the impact on mortality of the steroid treatment. When adjusting these results including the propensity score as a covariate, in-hospital mortality remained significantly lower in the steroid group (OR 0.774 [0.660 to 0.907], p = 0.002). Steroid treatment reduced mortality by 24% relative to no steroid treatment (RRR 0.24). These results support the use of glucocorticoids in COVID-19 in this subgroup of patients.
%K Corticosteroids
%K SARS-CoV-2
%K COVID-19
%K Mortality
%K Corticoesteroides
%K Mortalidad
%K Glucocorticoides
%K Estudios retrospectivos
%~